Repository Home

Summary Statistics

You can filter the data below or go straight to the results. Descriptions of the various cell types we distribute, such as CPLs and LCLs, can be found here. Information on ordering biomaterials can be found here.

Filters

Clear all filters

Disease Distributions

Subjects are grouped into distributions according to the way they were ascertained for their respective studies. This should not be confused with clinical diagnoses. Subjects in the Nicotine Dependence distribution, for example, may or may not be diagnosed with Nicotine Dependence. By default, all distributions are used.

Clinical Diagnoses

The definition of "Affected" depends on the study. The definition for the primary phenotype of each study is shown in the study breakdown section below unless hidden via the option above.

Dependence

Alcohol Dependence:

Cannabis Dependence:

Cocaine Dependence:

Nicotine Dependence:

Opioid Dependence:

Sedative Dependence:

Stimulant Dependence:

Other Dependence:

Abuse

Alcohol Abuse:

Cannabis Abuse:

Cocaine Abuse:

Opioid Abuse:

Sedative Abuse:

Stimulant Abuse:

Other Abuse:

Multiple Diagnosis Logic*: OR AND

*Example: when OR is selected, if you select both Nicotine and Alcohol dependence you get statistics for the combined set Nicotine-dependent subjects and Alcohol-dependent subjects. When AND is selected, you get statistics for subjects that are both Nicotine-dependent and Alcohol-dependent.

Demographics, Biomaterials and Clinical Instruments

Sex:

Age:Between and

Self-Identified Race/Ethnicity:

Has DNA:

Cell Types:

Cell Types Logic: OR AND

Cell type descriptions can be found here.

Clinical Instrument(s):

Clear all filters

Results

Filters Applied

To share these results with others, including any filters applied, click the box below to copy a link to this page to your clipboard:

Copy URL to Clipboard

Breakdown by Disease Distribution

Cell type descriptions (LCLs, CPLs, etc) can be found here.

Distribution Subjects With DNA Plasma LCLs CPLs Whole Blood
Nicotine Dependence 15,593 13,230 (85%) 2,467 (16%) 7,716 (49%) 12,636 (81%) 4,658 (30%)
Total 15,593 13,230 (85%) 2,467 (16%) 7,716 (49%) 12,636 (81%) 4,658 (30%)

Demographics, DNA and Clinical Instruments

Item Value
Subjects 15,593
With DNA 13,230 (85%)
Instrument: DSM-IV 8,691 (56%)
Instrument: DSM-III-R 115 (1%)
Instrument: Unknown 6,787 (44%)
Females / Males / Unknown 8,636 (55%) / 6,929 (44%) / 28 (0%)
Age Average: 43.1, Min: 12, Max: 88

Self-Identified Race/Ethnicity

Race/Ethnicity Subjects
White Non-Hispanic 9,891 (63%)
African-American 5,085 (33%)
Other 453 ( 3%)
White Hispanic 91 ( 1%)
Asian 50 ( 0%)
Missing 17 ( 0%)
American Indian 6 ( 0%)

Cell Types

Cell type descriptions (LCLs, CPLs, etc) can be found here.

Cell Type Subjects
LCL 7,716 (49%)
CPL 12,636 (81%)
LCL gDNA 7,493 (48%)
WB gDNA 6,881 (44%)
Plasma 2,467 (16%)
Whole Blood 4,658 (30%)

Diagnoses

Disease Affected* Unaffected Other
Alcohol Dependence 1,592 (10%) 6,815 (44%) 7,186 (46%)
Cannabis Dependence 858 ( 6%) 7,773 (50%) 6,962 (45%)
Cocaine Dependence 436 ( 3%) 8,302 (53%) 6,855 (44%)
Nicotine Dependence 5,280 (34%) 3,441 (22%) 6,872 (44%)
Opioid Dependence 120 ( 1%) 6,835 (44%) 8,638 (55%)
Other Drug Dependence 244 ( 2%) 8,484 (54%) 6,865 (44%)
Sedative Dependence 32 ( 0%) 3,544 (23%) 12,017 (77%)
Stimulant Dependence 75 ( 0%) 3,501 (22%) 12,017 (77%)
Alcohol Abuse 535 ( 3%) 2,311 (15%) 12,747 (82%)
Cannabis Abuse 308 ( 2%) 3,269 (21%) 12,016 (77%)
Cocaine Abuse 58 ( 0%) 3,517 (23%) 12,018 (77%)
Opioid Abuse 29 ( 0%) 3,546 (23%) 12,018 (77%)
Other Drug Abuse 129 ( 1%) 3,447 (22%) 12,017 (77%)
Sedative Abuse 33 ( 0%) 3,543 (23%) 12,017 (77%)
Stimulant Abuse 51 ( 0%) 3,525 (23%) 12,017 (77%)

*The definition of affected depends on the study and is shown in the study breakdown below (unless hidden via the option above).

Breakdown by NIDA Studies

Cell type descriptions (LCLs, CPLs, etc) can be found here. The "Definition of Affected" refers to the primary phenotype of the study.

Nicotine Dependence
Study Name PI Definition of Affected N With DNA Plasma LCLs CPLs Whole Blood
NicSNP The NicSNP Study Laura Bierut FTND >= 4 1,927 1,927 (100%) 515 (27%) 1,340 (70%) 1,878 (97%) 772 (40%)
2 Mapping Susceptibility Genes for Nicotine Dependence Ming D. Li DSM Nicotine Dependence or FTND>=4 2,803 1,962 (70%) 0 ( 0%) 1,961 (70%) 1,837 (66%) 148 ( 5%)
6 The Genetics of Vulnerability to Nicotine Pamela Madden DSM Nicotine Dependence or FTND>=4 3,446 2,344 (68%) 0 ( 0%) 2,330 (68%) 2,156 (63%) 30 ( 1%)
9 Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics Consortium Ovide Pomerleau DSM Nicotine Dependence or FTND>=4 or 5 cigs/day for 5 years and current 6 months 1,565 1,540 (98%) 0 ( 0%) 607 (39%) 1,502 (96%) 887 (57%)
10 Pharmacokinetics of Nicotine in Twins Gary Swan DSM Nicotine Dependence or FTND>=4 124 62 (50%) 0 ( 0%) 62 (50%) 60 (48%) 0 ( 0%)
15 Nicotine Dependence Laura Bierut DSM Nicotine Dependence or FTND>=4 2,146 1,813 (84%) 876 (41%) 854 (40%) 1,760 (82%) 1,131 (53%)
16 Nicotine Dependence Mark Leppert DSM Nicotine Dependence or FTND>=4 917 917 (100%) 2 ( 0%) 359 (39%) 821 (90%) 535 (58%)
27 The Genetic Study of Nicotine Dependence in African Americans (AAND) Laura Bierut DSM Nicotine Dependence or FTND>=4 1,792 1,792 (100%) 206 (11%) 194 (11%) 1,753 (98%) 1,134 (63%)
35 Genetically Informative Smoking Cessation Trial Li-Shiun Chen Active smoking (Cigarettes Per Day [CPD] ≥5) and exhaled Carbon Monoxide [CO] ≥8 ppm 873 873 (100%) 868 (99%) 9 ( 1%) 869 (100%) 21 ( 2%)
Total 15,593 13,230 (85%) 2,467 (16%) 7,716 (49%) 12,636 (81%) 4,658 (30%)

cell_file version: 2023-11-14 #2